|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 334.90 CHF | -1.35% |
|
+2.01% | +2.04% |
| 07-15 | Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns | MT |
| 07-15 | Roche's Gazyva/Gazyvaro Lands Priority Review From US FDA in Nephropathy | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +1.42% | -3.78% | +4.31% | +29.53% | +8.96% | +48.26% | +161.87% | +403.71% | +1,364.58% | 1,031B | |
| +0.70% | -4.22% | +5.52% | +5.80% | +19.91% | +50.60% | +56.00% | +47.62% | +101.52% | 595B | |
| +3.10% | +0.67% | +13.09% | +20.38% | +10.11% | +32.01% | +86.59% | +114.11% | +295.82% | 431B | |
| +1.03% | -0.84% | +2.97% | +4.97% | +12.46% | +29.58% | +45.15% | +45.92% | +53.21% | 277B | |
| +0.49% | -5.44% | -4.94% | -15.03% | -8.43% | +21.00% | +23.80% | +51.41% | +178.95% | 263B | |
| +1.59% | +4.89% | +19.80% | +30.56% | +3.24% | -22.56% | -37.35% | +20.83% | +80.44% | 224B | |
| +2.85% | +1.32% | +5.91% | +5.44% | +12.56% | +23.20% | +61.69% | +48.57% | +126.11% | 193B | |
| +2.16% | -0.32% | +5.64% | -2.99% | +9.51% | +22.36% | +73.48% | +95.85% | +54.62% | 164B | |
| +0.87% | +3.40% | -3.71% | -7.88% | +0.70% | +1.89% | -30.08% | -37.86% | -31.56% | 141B | |
| +1.15% | -2.87% | +6.42% | +10.70% | +6.37% | +2.70% | +34.71% | +138.41% | +439.31% | 121B | |
| +1.91% | +3.17% | +6.89% | +1.38% | +10.82% | +26.72% | -3.35% | -11.18% | -21.31% | 120B | |
| +0.89% | +0.60% | +1.69% | -4.84% | -6.99% | -7.52% | -18.29% | -12.44% | +2.35% | 105B | |
| +2.06% | -0.18% | +0.31% | -7.87% | +7.21% | +37.60% | +48.34% | +9.84% | -5.28% | 103B | |
| +1.59% | -1.42% | -2.52% | -16.36% | -12.16% | +5.72% | +87.01% | +75.75% | +471.66% | 72.37B | |
| -.--% | +1.73% | - | - | - | - | - | - | - | 63.66B | |
| +0.02% | -5.88% | +32.52% | +17.28% | +28.94% | +73.12% | -4.98% | -5.82% | -48.63% | 53.61B | |
| -2.63% | +3.67% | +16.94% | -3.01% | -6.01% | -2.15% | +17.82% | -7.10% | +249.38% | 55.95B | |
| +1.08% | -1.94% | +5.05% | -5.47% | +10.55% | +20.25% | +24.19% | +42.27% | +22.17% | 51.54B | |
| +3.03% | +2.75% | +11.04% | +4.99% | -1.25% | +2.81% | +16.86% | - | - | 42.68B | |
| Average | +1.16% | -2.24% | +7.05% | +3.76% | +5.92% | +20.31% | +35.75% | +59.99% | +196.08% | 216.2B | |
| Weighted average by Cap. | +1.35% | -3.69% | +5.92% | +11.39% | +8.50% | +30.35% | +70.11% | +141.60% | +450.09% |
- Stock Market
- Stocks
- ROP Stock
- ROG Stock
- Sector Roche Holding AG
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition